AVDL VS AMLX Stock Comparison

Performance

AVDL
100/100

AVDL returned 58.04% in the last 12 months. Based on SPY's performance of -21.06%, its performance is above average giving it a score of 100 of 100.

AMLX
10/100

AMLX returned -62.70% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

AVDL
80/100

5 analysts offer 12-month price targets for AVDL. Together, they have an average target of 10.67, the most optimistic target put AVDL at 12 within 12-months and the most pessimistic has AVDL at 9.

AMLX

"Analyst Price Targets" not found for AMLX

Sentiment

AVDL
70/100

AVDL had a bullish sentiment score of 70.23% across Twitter and StockTwits over the last 12 months. It had an average of 6.78 posts, 3.03 comments, and 4.97 likes per day.

AMLX

"Sentiment" not found for AMLX

Technicals

AVDL
11/100

AVDL receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

AMLX
18/100

AMLX receives a 17 of 100 based on 14 indicators. 2 are bullish, 11 are bearish.

Earnings

AVDL
10/100

AVDL has missed earnings 7 times in the last 20 quarters.

AMLX
10/100

AMLX has missed earnings 4 times in the last 20 quarters.

Profit

AVDL
10/100

Out of the last 20 quarters, AVDL has had 1 profitable quarters and has increased their profits year over year on 1 of them.

AMLX
33/100

Out of the last 12 quarters, AMLX has had 3 profitable quarters and has increased their profits year over year on 3 of them.

Volatility

AVDL
56/100

AVDL has had a higher than average amount of volatility over the last 12 months giving it a score of 55 of 100.

AMLX
43/100

AMLX has had a lower than average amount of volatility over the last 12 months giving it a score of 43 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Avadel Pharmaceuticals plc Ordinary Share Summary

Nasdaq / AVDL

Healthcare

Drug Manufacturers - Specialty & Generic

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Amylyx Pharmaceuticals, Inc. Common Stock Summary

Nasdaq / AMLX

Healthcare

Biotechnology

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Power up your portfolio